Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K S Balaggan

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Gene Therapy|November 5, 2011
Ocular gene delivery using lentiviral vectorsK S Balaggan, R R Ali
The Journal of Gene Medicine|November 22, 2005
Stable and efficient intraocular gene transfer using pseudotyped EIAV lentiviral vectorsK S Balaggan, K Binley, M Esapa, et al.
Gene Therapy|January 22, 2005
Long-term preservation of retinal function in the RCS rat model of retinitis pigmentosa following lentivirus-mediated gene therapyM Tschernutter, F C Schlichtenbrede, S Howe, et al.
Gene Therapy|November 25, 2011
Absence of ocular malignant transformation after sub-retinal delivery of rAAV2/2 or integrating lentiviral vectors in p53-deficient miceK S Balaggan, Y Duran, A Georgiadis, et al.
Gene Therapy|March 31, 2006
EIAV vector-mediated delivery of endostatin or angiostatin inhibits angiogenesis and vascular hyperpermeability in experimental CNVK S Balaggan, K Binley, M Esapa, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Gene Therapy|November 5, 2011
Ocular gene delivery using lentiviral vectorsK S Balaggan, R R Ali
The Journal of Gene Medicine|November 22, 2005
Stable and efficient intraocular gene transfer using pseudotyped EIAV lentiviral vectorsK S Balaggan, K Binley, M Esapa, et al.
Gene Therapy|January 22, 2005
Long-term preservation of retinal function in the RCS rat model of retinitis pigmentosa following lentivirus-mediated gene therapyM Tschernutter, F C Schlichtenbrede, S Howe, et al.
Gene Therapy|November 25, 2011
Absence of ocular malignant transformation after sub-retinal delivery of rAAV2/2 or integrating lentiviral vectors in p53-deficient miceK S Balaggan, Y Duran, A Georgiadis, et al.
Gene Therapy|March 31, 2006
EIAV vector-mediated delivery of endostatin or angiostatin inhibits angiogenesis and vascular hyperpermeability in experimental CNVK S Balaggan, K Binley, M Esapa, et al.
Pageof 1